Axsome Therapeutics (AXSM) Income from Continuing Operations (2015 - 2026)
Axsome Therapeutics (AXSM) posted Income from Continuing Operations of 64542000.0 for Q1 2026, down 125.43% sequentially from 28631000.0 in Q4 2025, and down 8.63% YoY from 70640222.64 in Q1 2025.
Powered by 
Analysis
Axsome Therapeutics (AXSM) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Axsome Therapeutics has reported Income from Continuing Operations for 12 years, with the latest figure at 64542000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 8.63% year-over-year to 64542000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 188375000.0 (up 32.31% YoY) and the FY2025 annual result came in at 183206000.0, up 36.21% from the prior year.
- Income from Continuing Operations declined to 64542000.0 in Q1 2026 per AXSM's latest filing, from 28631000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 11238000.0 in Q1 2023 and troughed at 98636000.0 in Q4 2023.
- A 5-year average of 56552823.53 and a median of 61241000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations jumped 81.04% in 2022, then slumped 508.27% in 2024.
- Over 5 years, Income from Continuing Operations stood at 61241000.0 in 2022, then slumped by 61.06% to 98636000.0 in 2023, then grew by 24.05% to 74912000.0 in 2024, then soared by 61.78% to 28631000.0 in 2025, then slumped by 125.43% to 64542000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 64542000.0, 28631000.0, and 47229000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Axsome Therapeutics | 10.73 Bn | 10.41 Bn | 204.81 Mn | -51.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -51.31 Mn |
| Mar 31, 2026 | -64.54 Mn |
| Dec 31, 2025 | 9.35 Mn |
| Sep 30, 2025 | -47.23 Mn |
| Jun 30, 2025 | -47.93 Mn |
| Mar 31, 2025 | -59.41 Mn |
| Dec 31, 2024 | -74.91 Mn |
| Sep 30, 2024 | -64.60 Mn |
| Jun 30, 2024 | -79.35 Mn |
| Mar 31, 2024 | -68.36 Mn |
| Dec 31, 2023 | -98.64 Mn |
| Sep 30, 2023 | -62.18 Mn |
| Jun 30, 2023 | -67.17 Mn |
| Mar 31, 2023 | -11.24 Mn |
| Dec 31, 2022 | -61.24 Mn |
| Sep 30, 2022 | -44.82 Mn |
| Jun 30, 2022 | -41.44 Mn |
| Mar 31, 2022 | -39.63 Mn |
| Dec 31, 2021 | -33.98 Mn |
| Sep 30, 2021 | -34.88 Mn |